Global Pulmonary Fibrosis Drug Market Research Report 2023
Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
According to QYResearch’s new survey, global Pulmonary Fibrosis Drug market is projected to reach US$ 6088.1 million in 2029, increasing from US$ 4325 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pulmonary Fibrosis Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pulmonary Fibrosis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global Pulmonary Fibrosis Drug market is projected to reach US$ 6088.1 million in 2029, increasing from US$ 4325 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pulmonary Fibrosis Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pulmonary Fibrosis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Boehringer Ingelheim
- Roche
- FibroGen, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- MediciNova, Inc.
- Genentech, Inc.
- Cipla Inc.
- Biogen
- Galapagos NV
- Pirfenidone
- Nintedanib
- Hospital
- Clinic
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 PULMONARY FIBROSIS DRUG MARKET OVERVIEW
1.1 Product Overview and Scope of Pulmonary Fibrosis Drug
1.2 Pulmonary Fibrosis Drug Segment by Type
1.2.1 Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029)
1.2.2 Pirfenidone
1.2.3 Nintedanib
1.3 Pulmonary Fibrosis Drug Segment by Application
1.3.1 Global Pulmonary Fibrosis Drug Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Fibrosis Drug Revenue 2018-2029
1.4.2 Global Pulmonary Fibrosis Drug Sales 2018-2029
1.4.3 Global Pulmonary Fibrosis Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PULMONARY FIBROSIS DRUG MARKET COMPETITION BY MANUFACTURERS
2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2018-2023)
2.4 Global Pulmonary Fibrosis Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
2.7 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
2.7.1 Pulmonary Fibrosis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
2.7.3 Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PULMONARY FIBROSIS DRUG RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Pulmonary Fibrosis Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Pulmonary Fibrosis Drug Global Pulmonary Fibrosis Drug Sales by Region: 2018-2029
3.2.1 Global Pulmonary Fibrosis Drug Sales by Region: 2018-2023
3.2.2 Global Pulmonary Fibrosis Drug Sales by Region: 2024-2029
3.3 Global Pulmonary Fibrosis Drug Global Pulmonary Fibrosis Drug Revenue by Region: 2018-2029
3.3.1 Global Pulmonary Fibrosis Drug Revenue by Region: 2018-2023
3.3.2 Global Pulmonary Fibrosis Drug Revenue by Region: 2024-2029
3.4 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.4.1 North America Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.4.3 North America Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.5.1 Europe Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.5.3 Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.7.3 Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Pulmonary Fibrosis Drug Sales by Type (2018-2029)
4.1.1 Global Pulmonary Fibrosis Drug Sales by Type (2018-2023)
4.1.2 Global Pulmonary Fibrosis Drug Sales by Type (2024-2029)
4.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
4.2 Global Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
4.2.1 Global Pulmonary Fibrosis Drug Revenue by Type (2018-2023)
4.2.2 Global Pulmonary Fibrosis Drug Revenue by Type (2024-2029)
4.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Pulmonary Fibrosis Drug Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Pulmonary Fibrosis Drug Sales by Application (2018-2029)
5.1.1 Global Pulmonary Fibrosis Drug Sales by Application (2018-2023)
5.1.2 Global Pulmonary Fibrosis Drug Sales by Application (2024-2029)
5.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
5.2 Global Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
5.2.1 Global Pulmonary Fibrosis Drug Revenue by Application (2018-2023)
5.2.2 Global Pulmonary Fibrosis Drug Revenue by Application (2024-2029)
5.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Pulmonary Fibrosis Drug Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Corporation Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 FibroGen, Inc.
6.3.1 FibroGen, Inc. Corporation Information
6.3.2 FibroGen, Inc. Description and Business Overview
6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.3.5 FibroGen, Inc. Recent Developments/Updates
6.4 Merck & Co., Inc.
6.4.1 Merck & Co., Inc. Corporation Information
6.4.2 Merck & Co., Inc. Description and Business Overview
6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
6.4.5 Merck & Co., Inc. Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Corporation Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 MediciNova, Inc.
6.6.1 MediciNova, Inc. Corporation Information
6.6.2 MediciNova, Inc. Description and Business Overview
6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.6.5 MediciNova, Inc. Recent Developments/Updates
6.7 Genentech, Inc.
6.6.1 Genentech, Inc. Corporation Information
6.6.2 Genentech, Inc. Description and Business Overview
6.6.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.7.5 Genentech, Inc. Recent Developments/Updates
6.8 Cipla Inc.
6.8.1 Cipla Inc. Corporation Information
6.8.2 Cipla Inc. Description and Business Overview
6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
6.8.5 Cipla Inc. Recent Developments/Updates
6.9 Biogen
6.9.1 Biogen Corporation Information
6.9.2 Biogen Description and Business Overview
6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
6.9.5 Biogen Recent Developments/Updates
6.10 Galapagos NV
6.10.1 Galapagos NV Corporation Information
6.10.2 Galapagos NV Description and Business Overview
6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
6.10.5 Galapagos NV Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Pulmonary Fibrosis Drug Industry Chain Analysis
7.2 Pulmonary Fibrosis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Fibrosis Drug Production Mode & Process
7.4 Pulmonary Fibrosis Drug Sales and Marketing
7.4.1 Pulmonary Fibrosis Drug Sales Channels
7.4.2 Pulmonary Fibrosis Drug Distributors
7.5 Pulmonary Fibrosis Drug Customers
8 PULMONARY FIBROSIS DRUG MARKET DYNAMICS
8.1 Pulmonary Fibrosis Drug Industry Trends
8.2 Pulmonary Fibrosis Drug Market Drivers
8.3 Pulmonary Fibrosis Drug Market Challenges
8.4 Pulmonary Fibrosis Drug Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Pulmonary Fibrosis Drug
1.2 Pulmonary Fibrosis Drug Segment by Type
1.2.1 Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029)
1.2.2 Pirfenidone
1.2.3 Nintedanib
1.3 Pulmonary Fibrosis Drug Segment by Application
1.3.1 Global Pulmonary Fibrosis Drug Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Fibrosis Drug Revenue 2018-2029
1.4.2 Global Pulmonary Fibrosis Drug Sales 2018-2029
1.4.3 Global Pulmonary Fibrosis Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PULMONARY FIBROSIS DRUG MARKET COMPETITION BY MANUFACTURERS
2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2018-2023)
2.4 Global Pulmonary Fibrosis Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
2.7 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
2.7.1 Pulmonary Fibrosis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
2.7.3 Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PULMONARY FIBROSIS DRUG RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Pulmonary Fibrosis Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Pulmonary Fibrosis Drug Global Pulmonary Fibrosis Drug Sales by Region: 2018-2029
3.2.1 Global Pulmonary Fibrosis Drug Sales by Region: 2018-2023
3.2.2 Global Pulmonary Fibrosis Drug Sales by Region: 2024-2029
3.3 Global Pulmonary Fibrosis Drug Global Pulmonary Fibrosis Drug Revenue by Region: 2018-2029
3.3.1 Global Pulmonary Fibrosis Drug Revenue by Region: 2018-2023
3.3.2 Global Pulmonary Fibrosis Drug Revenue by Region: 2024-2029
3.4 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.4.1 North America Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.4.3 North America Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.5.1 Europe Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.5.3 Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.7.3 Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Pulmonary Fibrosis Drug Sales by Type (2018-2029)
4.1.1 Global Pulmonary Fibrosis Drug Sales by Type (2018-2023)
4.1.2 Global Pulmonary Fibrosis Drug Sales by Type (2024-2029)
4.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
4.2 Global Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
4.2.1 Global Pulmonary Fibrosis Drug Revenue by Type (2018-2023)
4.2.2 Global Pulmonary Fibrosis Drug Revenue by Type (2024-2029)
4.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Pulmonary Fibrosis Drug Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Pulmonary Fibrosis Drug Sales by Application (2018-2029)
5.1.1 Global Pulmonary Fibrosis Drug Sales by Application (2018-2023)
5.1.2 Global Pulmonary Fibrosis Drug Sales by Application (2024-2029)
5.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
5.2 Global Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
5.2.1 Global Pulmonary Fibrosis Drug Revenue by Application (2018-2023)
5.2.2 Global Pulmonary Fibrosis Drug Revenue by Application (2024-2029)
5.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Pulmonary Fibrosis Drug Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Corporation Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 FibroGen, Inc.
6.3.1 FibroGen, Inc. Corporation Information
6.3.2 FibroGen, Inc. Description and Business Overview
6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.3.5 FibroGen, Inc. Recent Developments/Updates
6.4 Merck & Co., Inc.
6.4.1 Merck & Co., Inc. Corporation Information
6.4.2 Merck & Co., Inc. Description and Business Overview
6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
6.4.5 Merck & Co., Inc. Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Corporation Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 MediciNova, Inc.
6.6.1 MediciNova, Inc. Corporation Information
6.6.2 MediciNova, Inc. Description and Business Overview
6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.6.5 MediciNova, Inc. Recent Developments/Updates
6.7 Genentech, Inc.
6.6.1 Genentech, Inc. Corporation Information
6.6.2 Genentech, Inc. Description and Business Overview
6.6.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.7.5 Genentech, Inc. Recent Developments/Updates
6.8 Cipla Inc.
6.8.1 Cipla Inc. Corporation Information
6.8.2 Cipla Inc. Description and Business Overview
6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
6.8.5 Cipla Inc. Recent Developments/Updates
6.9 Biogen
6.9.1 Biogen Corporation Information
6.9.2 Biogen Description and Business Overview
6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
6.9.5 Biogen Recent Developments/Updates
6.10 Galapagos NV
6.10.1 Galapagos NV Corporation Information
6.10.2 Galapagos NV Description and Business Overview
6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
6.10.5 Galapagos NV Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Pulmonary Fibrosis Drug Industry Chain Analysis
7.2 Pulmonary Fibrosis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Fibrosis Drug Production Mode & Process
7.4 Pulmonary Fibrosis Drug Sales and Marketing
7.4.1 Pulmonary Fibrosis Drug Sales Channels
7.4.2 Pulmonary Fibrosis Drug Distributors
7.5 Pulmonary Fibrosis Drug Customers
8 PULMONARY FIBROSIS DRUG MARKET DYNAMICS
8.1 Pulmonary Fibrosis Drug Industry Trends
8.2 Pulmonary Fibrosis Drug Market Drivers
8.3 Pulmonary Fibrosis Drug Market Challenges
8.4 Pulmonary Fibrosis Drug Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Pulmonary Fibrosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Pulmonary Fibrosis Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Pulmonary Fibrosis Drug Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Pulmonary Fibrosis Drug Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
Table 12. Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 18. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2023)
Table 19. Global Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2024-2029)
Table 21. Global Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2023)
Table 23. Global Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 27. North America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 32. Europe Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2023)
Table 51. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Table 53. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2024-2029)
Table 54. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Table 57. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2018-2023)
Table 59. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2018-2023)
Table 61. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Table 63. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2024-2029)
Table 64. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2023)
Table 67. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2018-2023)
Table 69. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2024-2029)
Table 70. Boehringer Ingelheim Corporation Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Boehringer Ingelheim Pulmonary Fibrosis Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Roche Pulmonary Fibrosis Drug Product
Table 79. Roche Recent Developments/Updates
Table 80. FibroGen, Inc. Corporation Information
Table 81. FibroGen, Inc. Description and Business Overview
Table 82. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. FibroGen, Inc. Pulmonary Fibrosis Drug Product
Table 84. FibroGen, Inc. Recent Developments/Updates
Table 85. Merck & Co., Inc. Corporation Information
Table 86. Merck & Co., Inc. Description and Business Overview
Table 87. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Merck & Co., Inc. Pulmonary Fibrosis Drug Product
Table 89. Merck & Co., Inc. Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Corporation Information
Table 91. Bristol-Myers Squibb Company Description and Business Overview
Table 92. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product
Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
Table 95. MediciNova, Inc. Corporation Information
Table 96. MediciNova, Inc. Description and Business Overview
Table 97. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. MediciNova, Inc. Pulmonary Fibrosis Drug Product
Table 99. MediciNova, Inc. Recent Developments/Updates
Table 100. Genentech, Inc. Corporation Information
Table 101. Genentech, Inc. Description and Business Overview
Table 102. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Genentech, Inc. Pulmonary Fibrosis Drug Product
Table 104. Genentech, Inc. Recent Developments/Updates
Table 105. Cipla Inc. Corporation Information
Table 106. Cipla Inc. Description and Business Overview
Table 107. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Cipla Inc. Pulmonary Fibrosis Drug Product
Table 109. Cipla Inc. Recent Developments/Updates
Table 110. Biogen Corporation Information
Table 111. Biogen Description and Business Overview
Table 112. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Biogen Pulmonary Fibrosis Drug Product
Table 114. Biogen Recent Developments/Updates
Table 115. Galapagos NV Corporation Information
Table 116. Galapagos NV Description and Business Overview
Table 117. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Galapagos NV Pulmonary Fibrosis Drug Product
Table 119. Galapagos NV Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Pulmonary Fibrosis Drug Distributors List
Table 123. Pulmonary Fibrosis Drug Customers List
Table 124. Pulmonary Fibrosis Drug Market Trends
Table 125. Pulmonary Fibrosis Drug Market Drivers
Table 126. Pulmonary Fibrosis Drug Market Challenges
Table 127. Pulmonary Fibrosis Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 1. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Pulmonary Fibrosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Pulmonary Fibrosis Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Pulmonary Fibrosis Drug Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Pulmonary Fibrosis Drug Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
Table 12. Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 18. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2023)
Table 19. Global Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2024-2029)
Table 21. Global Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2023)
Table 23. Global Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 27. North America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 32. Europe Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2023)
Table 51. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Table 53. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2024-2029)
Table 54. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Table 57. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2018-2023)
Table 59. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2018-2023)
Table 61. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Table 63. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2024-2029)
Table 64. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2023)
Table 67. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2018-2023)
Table 69. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2024-2029)
Table 70. Boehringer Ingelheim Corporation Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Boehringer Ingelheim Pulmonary Fibrosis Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Roche Pulmonary Fibrosis Drug Product
Table 79. Roche Recent Developments/Updates
Table 80. FibroGen, Inc. Corporation Information
Table 81. FibroGen, Inc. Description and Business Overview
Table 82. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. FibroGen, Inc. Pulmonary Fibrosis Drug Product
Table 84. FibroGen, Inc. Recent Developments/Updates
Table 85. Merck & Co., Inc. Corporation Information
Table 86. Merck & Co., Inc. Description and Business Overview
Table 87. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Merck & Co., Inc. Pulmonary Fibrosis Drug Product
Table 89. Merck & Co., Inc. Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Corporation Information
Table 91. Bristol-Myers Squibb Company Description and Business Overview
Table 92. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product
Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
Table 95. MediciNova, Inc. Corporation Information
Table 96. MediciNova, Inc. Description and Business Overview
Table 97. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. MediciNova, Inc. Pulmonary Fibrosis Drug Product
Table 99. MediciNova, Inc. Recent Developments/Updates
Table 100. Genentech, Inc. Corporation Information
Table 101. Genentech, Inc. Description and Business Overview
Table 102. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Genentech, Inc. Pulmonary Fibrosis Drug Product
Table 104. Genentech, Inc. Recent Developments/Updates
Table 105. Cipla Inc. Corporation Information
Table 106. Cipla Inc. Description and Business Overview
Table 107. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Cipla Inc. Pulmonary Fibrosis Drug Product
Table 109. Cipla Inc. Recent Developments/Updates
Table 110. Biogen Corporation Information
Table 111. Biogen Description and Business Overview
Table 112. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Biogen Pulmonary Fibrosis Drug Product
Table 114. Biogen Recent Developments/Updates
Table 115. Galapagos NV Corporation Information
Table 116. Galapagos NV Description and Business Overview
Table 117. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Galapagos NV Pulmonary Fibrosis Drug Product
Table 119. Galapagos NV Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Pulmonary Fibrosis Drug Distributors List
Table 123. Pulmonary Fibrosis Drug Customers List
Table 124. Pulmonary Fibrosis Drug Market Trends
Table 125. Pulmonary Fibrosis Drug Market Drivers
Table 126. Pulmonary Fibrosis Drug Market Challenges
Table 127. Pulmonary Fibrosis Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Pulmonary Fibrosis Drug
Figure 2. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Pulmonary Fibrosis Drug Market Share by Type in 2022 & 2029
Figure 4. Pirfenidone Product Picture
Figure 5. Nintedanib Product Picture
Figure 6. Global Pulmonary Fibrosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Pulmonary Fibrosis Drug Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Pulmonary Fibrosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Pulmonary Fibrosis Drug Market Size (2018-2029) & (US$ Million)
Figure 12. Global Pulmonary Fibrosis Drug Sales (2018-2029) & (K Units)
Figure 13. Global Pulmonary Fibrosis Drug Average Price (US$/Unit) & (2018-2029)
Figure 14. Pulmonary Fibrosis Drug Report Years Considered
Figure 15. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2022
Figure 16. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Pulmonary Fibrosis Drug Players: Market Share by Revenue in 2022
Figure 18. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 19. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 20. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 21. North America Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 22. United States Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 23. Canada Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 25. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 26. Germany Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. France Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. U.K. Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Italy Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Russia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2029)
Figure 32. Asia Pacific Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2029)
Figure 33. China Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Japan Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. South Korea Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. India Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Australia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. China Taiwan Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Indonesia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Thailand Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Malaysia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 43. Latin America Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Pulmonary Fibrosis Drug by Type (2018-2029)
Figure 53. Global Revenue Market Share of Pulmonary Fibrosis Drug by Type (2018-2029)
Figure 54. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Pulmonary Fibrosis Drug by Application (2018-2029)
Figure 56. Global Revenue Market Share of Pulmonary Fibrosis Drug by Application (2018-2029)
Figure 57. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2018-2029)
Figure 58. Pulmonary Fibrosis Drug Value Chain
Figure 59. Pulmonary Fibrosis Drug Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Figure 1. Product Picture of Pulmonary Fibrosis Drug
Figure 2. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Pulmonary Fibrosis Drug Market Share by Type in 2022 & 2029
Figure 4. Pirfenidone Product Picture
Figure 5. Nintedanib Product Picture
Figure 6. Global Pulmonary Fibrosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Pulmonary Fibrosis Drug Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Pulmonary Fibrosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Pulmonary Fibrosis Drug Market Size (2018-2029) & (US$ Million)
Figure 12. Global Pulmonary Fibrosis Drug Sales (2018-2029) & (K Units)
Figure 13. Global Pulmonary Fibrosis Drug Average Price (US$/Unit) & (2018-2029)
Figure 14. Pulmonary Fibrosis Drug Report Years Considered
Figure 15. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2022
Figure 16. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Pulmonary Fibrosis Drug Players: Market Share by Revenue in 2022
Figure 18. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 19. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 20. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 21. North America Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 22. United States Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 23. Canada Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 25. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 26. Germany Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. France Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. U.K. Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Italy Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Russia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2029)
Figure 32. Asia Pacific Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2029)
Figure 33. China Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Japan Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. South Korea Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. India Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Australia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. China Taiwan Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Indonesia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Thailand Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Malaysia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 43. Latin America Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Pulmonary Fibrosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Pulmonary Fibrosis Drug by Type (2018-2029)
Figure 53. Global Revenue Market Share of Pulmonary Fibrosis Drug by Type (2018-2029)
Figure 54. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Pulmonary Fibrosis Drug by Application (2018-2029)
Figure 56. Global Revenue Market Share of Pulmonary Fibrosis Drug by Application (2018-2029)
Figure 57. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2018-2029)
Figure 58. Pulmonary Fibrosis Drug Value Chain
Figure 59. Pulmonary Fibrosis Drug Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
